Co-Authors
This is a "connection" page, showing publications co-authored by NIZAR M TANNIR and ANA APARICIO.
Connection Strength
0.671
-
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
Score: 0.198
-
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30.
Score: 0.112
-
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
Score: 0.106
-
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009 Apr 01; 4(3):176-84.
Score: 0.084
-
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998.
Score: 0.050
-
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
Score: 0.046
-
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
Score: 0.045
-
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76.
Score: 0.031